Evaluation of Near-infrared Fluorescence-conjugated Peptides for Visualization of Human Epidermal Receptor 2-overexpressed Gastric Cancer

• Published in: Journal of gastric cancer Vol. 21; no. 2; pp. 191 - 202
• Main Authors: Jeong, Kyoungyun, Kong, Seong-Ho, Bae, Seong-Woo, Park, Cho Rong, Berlth, Felix, Shin, Jae Hwan, Lee, Yun-Sang, Youn, Hyewon, Koo, Eunhee, Suh, Yun-Suhk, Park, Do Joong, Lee, Hyuk-Joon, Yang, Han-Kwang
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Gastric Cancer Association 01.06.2021; 대한위암학회
• Subjects: Original; 일반외과학; Fluorescence; Gastrectomy; Surgery; Stomach neoplasms
• ISSN: 2093-582X; 2093-5641
• DOI: 10.5230/jgc.2021.21.e18

A near-infrared (NIR) fluorescence imaging is a promising tool for cancer-specific image guided surgery. Human epidermal receptor 2 (HER2) is one of the candidate markers for gastric cancer. In this study, we aimed to synthesize HER2-specific NIR fluorescence probes and evaluate their applicability in cancer-specific image-guided surgeries using an animal model. An NIR dye emitting light at 800 nm (IRDye800CW; Li-COR) was conjugated to trastuzumab and an HER2-specific affibody using a click mechanism. HER2 affinity was assessed using surface plasmon resonance. Gastric cancer cell lines (NCI-N87 and SNU-601) were subcutaneously implanted into female BALB/c nu (6-8 weeks old) mice. After intravenous injection of the probes, biodistribution and fluorescence signal intensity were measured using Lumina II (Perkin Elmer) and a laparoscopic NIR camera (InTheSmart). Trastuzumab-IRDye800CW exhibited high affinity for HER2 (K =2.093(3) pM). Fluorescence signals in the liver and spleen were the highest at 24 hours post injection, while the signal in HER2-positive tumor cells increased until 72 hours, as assessed using the Lumina II system. The signal corresponding to the tumor was visually identified and clearly differentiated from the liver after 72 hours using a laparoscopic NIR camera. Affibody-IRDye800CW also exhibited high affinity for HER2 (K =4.71 nM); however, the signal was not identified in the tumor, probably owing to rapid renal clearance. Trastuzumab-IRDye800CW may be used as a potential NIR probe that can be injected 2-3 days before surgery to obtain high HER2-specific signal and contrast. Affibody-based NIR probes may require modifications to enhance mobilization to the tumor site.